VEGF in turn promotes PD-1 expression, so it is clear how a combination of antiangiogenic therapy and ICIs can interrupt the cycle, improve the tumor microenvironment, and enhance the activity of T lymphocytes. This evidence concerns the gene VEGFA and neoplasm.